Dry vs Wet Macular Degeneration: How Each Form Progresses and Why Treatment Plans Differ

The letter looked fine until she reached the second line. The optometrist had asked her to read the chart with her left eye covered, and suddenly the middle of every word went soft, as if someone had smudged a thumb across the page. The edges were sharp. The center was not. Twenty minutes later she was hearing the phrase age-related macular degeneration for the first time, along with a second question she had never thought to ask: which kind?

That question turns out to matter more than almost anything else in the consultation. Dry vs wet macular degeneration is not a difference of degree, like mild versus severe. The two forms damage the same small patch of retina by different mechanisms, move at different speeds, and answer to different treatments. One is managed largely by watching and protecting. The other is treated with medicine injected into the eye, on a schedule that can last years.

Understanding that split is what turns a frightening diagnosis into a plan you can actually follow.

What actually happens in the macula when it degenerates

The macula is a patch of retina about the size of a pinhead, sitting at the back of the eye directly behind the pupil. Small as it is, it does the work you notice most: reading, recognizing a face across a room, threading a needle, seeing the road sign before you pass it. The rest of the retina handles peripheral vision, which is why macular degeneration almost never causes total blindness. It removes the center of the picture and leaves the frame.

Underneath the light-sensing photoreceptor cells lies a single layer of support cells called the retinal pigment epithelium, or RPE. Think of it as the macula’s housekeeping staff. Every day the photoreceptors shed used-up material, and the RPE clears it, recycles what it can and passes waste through a thin membrane to the blood supply below. That blood supply, the choroid, is one of the richest in the body.

Age-related macular degeneration, usually shortened to AMD, is what happens when this housekeeping system starts to fail. Waste accumulates in yellowish deposits called drusen. The RPE thins and dies in patches. In some eyes the choroid responds to the stress by growing new, fragile blood vessels that leak fluid and blood into layers where no fluid should be. Those two responses, slow decay and abrupt leakage, are the dry and wet forms respectively.

According to the National Eye Institute, AMD is a leading cause of vision loss in people over 55, and the dry form accounts for roughly 8 in 10 diagnoses. Wet AMD is less common but, as the Cleveland Clinic notes, is responsible for most of the severe vision loss the disease causes. That asymmetry, common but slow versus rare but fast, is the whole story in miniature.

Dry vs wet macular degeneration at a glance

Eye specialists tend to describe the two forms in terms of what they see on a retinal scan, while patients describe them in terms of what changed in their reading. Both descriptions are correct, and the table below lines them up. One caution before you read it: an eye can shift from the dry column to the wet column, and a person can have dry disease in one eye and wet in the other. The categories describe the current state of one eye, not a permanent label on a person.

Feature	Dry (atrophic) AMD	Wet (neovascular) AMD
Underlying process	Drusen build-up and gradual thinning of the RPE and photoreceptors	Abnormal choroidal blood vessels leaking fluid or blood under the retina
Share of AMD diagnoses	About 80 percent (NEI)	About 10 to 15 percent (Cleveland Clinic)
Typical pace	Years; often a decade or more from early changes to significant loss	Days to weeks; can worsen noticeably between two appointments
Early experience	Frequently none; slight need for brighter light, mild blur	Straight lines appearing bent, a dark or gray patch, sudden distortion
Advanced stage	Geographic atrophy: a permanent central blind spot	Scarring (disciform scar) if leakage is not controlled
Main treatment approach	Monitoring, risk-factor control, studied vitamin formulas, complement-inhibitor injections for atrophy	Anti-VEGF eye injections, repeated over months to years
Chance of reversing lost vision	Very low; treatments aim to slow	Some recovery is possible if treated early

The MedlinePlus overview describes the same division in plainer terms: dry AMD is the common, slower type, and wet AMD is the less common type that leads to more severe and faster loss. Everything that follows explains why each row in that table looks the way it does.

What are the hallmark signs of dry macular degeneration?

The most honest answer is that early dry AMD usually has no signs the person can feel. It is found, not felt. An optometrist dilating the pupils during a routine exam spots a scatter of small yellow drusen beneath the macula, or an optical coherence tomography scan, a painless imaging test that produces a cross-section of the retina, shows the RPE beginning to buckle. The NEI is clear that early AMD typically produces no symptoms at all, which is the strongest argument for routine dilated exams after midlife even when vision seems fine.

When symptoms do arrive, they come quietly. People describe needing the lamp closer to the book than they used to, or finding that a dimly lit restaurant menu has become unreadable while the same menu in daylight is fine. Colors may seem a little washed out. A word in the middle of a line goes slightly out of focus while the words either side stay crisp. Because the brain is good at filling gaps, and because the other eye often compensates, many people do not notice until one eye is covered.

What clinicians look for is different from what patients notice. The size and number of drusen matter: larger, softer, more confluent deposits carry higher risk than a few small hard ones. Pigment clumping in the RPE is another marker. In the advanced stage, called geographic atrophy, the RPE and photoreceptors have died away in a well-defined patch, and that patch corresponds to a permanent blind spot in central vision.

These observations are for context, not self-diagnosis. A change in reading vision has many possible causes, from a shift in glasses prescription to cataract, and only an eye examination can tell them apart.

Macular degeneration progression stages: how dry AMD advances

Clinicians describe dry AMD in three stages, and the boundaries between them are drawn from what appears on the retina rather than from how the person feels. The NEI framework runs from early, through intermediate, to late.

Early AMD means medium-sized drusen without pigment changes. Vision is usually normal. Many people at this stage will never progress meaningfully, and the appropriate response is periodic monitoring rather than treatment.

Intermediate AMD means large drusen, pigment abnormalities, or both. Some people notice mild blur or need more light. This is the stage at which the Age-Related Eye Disease Studies found that a specific antioxidant and mineral formula reduced the risk of moving to late disease. It is also the stage at which the risk of conversion to wet AMD becomes worth discussing.

Late dry AMD is geographic atrophy. Cells in the center of the macula have died, and the loss is permanent. The atrophic patch tends to enlarge slowly over years, and vision worsens in step with it. Whether it eventually engulfs the very center of the macula, the fovea, determines how much reading vision remains.

The pace of this journey is genuinely variable. The Mayo Clinic describes dry AMD as worsening gradually over years, and the AREDS simplified severity scale published in the Archives of Ophthalmology illustrates just how wide the range is: over five years, people with no large drusen or pigment changes in either eye had well under a one percent chance of developing advanced AMD, while those with both features in both eyes had roughly a one-in-two chance. Same diagnosis, wildly different trajectories, which is why a retina specialist reviewing your scans can give a more useful estimate than any general figure.

Wet macular degeneration symptoms and why the wet form moves faster

Wet AMD begins when the stressed, oxygen-hungry macula sends out a chemical distress signal called vascular endothelial growth factor, or VEGF. VEGF is a protein that tells blood vessels to grow. In a healing wound that is useful. Under the macula it is disastrous, because the new vessels that sprout from the choroid are abnormal, thin-walled and leaky. This process is called choroidal neovascularization. Fluid seeps under the retina, lifting it like a bubble under wallpaper. Sometimes the vessels bleed outright.

The speed comes from physics rather than biology. Drusen accumulate over years because waste builds up slowly. Fluid, by contrast, can pool within days, and even a small amount displaces photoreceptors from their normal position. That displacement is why the classic wet symptom is distortion: door frames bow, a printed line of text develops a wave in the middle, a face looks oddly stretched. The NHS describes wet AMD as getting worse quickly, sometimes in a few weeks, and notes that it can also produce a dark or blank patch in the center of vision. Distortion arriving over a short period is precisely the pattern that should prompt an urgent eye appointment rather than a wait for the next scheduled check.

Confirming wet AMD takes imaging. OCT shows fluid as dark pockets within or beneath the retina. Fluorescein angiography, where a dye is injected into an arm vein and photographed as it passes through the eye’s vessels, reveals the leaking network directly. OCT angiography can map blood flow without dye. These tests distinguish wet AMD from other causes of distortion, including a dry eye that has simply reached geographic atrophy, and they establish the baseline against which every future injection decision is measured.

How long does it take for dry macular degeneration to turn to wet?

There is no clock. That is the frustrating, truthful answer, and it is worth understanding why. Conversion to wet AMD is not a stage that dry disease inevitably reaches after a set number of years. It is an event, triggered when the macula’s VEGF signaling tips past a threshold and new vessels break through. Some eyes reach that point within a year or two of the first drusen being noticed. Many never reach it at all.

What the evidence does offer is probability. The Cleveland Clinic puts the proportion of people with dry AMD who go on to develop the wet form at roughly 10 to 15 percent. The AREDS simplified scale mentioned earlier adds nuance: risk climbs steeply with the number of high-risk features, meaning large drusen and pigment changes, and with whether one eye has already reached the advanced stage. If one eye has converted to wet AMD, the fellow eye is at materially higher risk than the general dry population, which is why specialists monitor the second eye so closely.

When conversion does happen, the transition itself is fast. This is the part people find counterintuitive. A person can have stable dry AMD for eight years and then develop distortion over a fortnight. The NHS advice to seek help quickly for sudden changes exists because anti-VEGF treatment works best before fluid has done lasting damage.

Practically, this means two things. First, the interval between eye checks for someone with intermediate dry AMD is a clinical judgment based on their scans, not a fixed rule. Second, home monitoring with an Amsler grid, a simple sheet of graph-paper lines used to check for new distortion, is not busywork. It is the early warning system between appointments.

Which is worse, dry or wet macular degeneration? An honest comparison

Ask this question of a retina specialist and you may get a thoughtful pause. Wet AMD is more dangerous in the moment: untreated, it can destroy central vision in months, and the Cleveland Clinic attributes the large majority of severe AMD vision loss to it. If the question is which form does more damage when nothing is done, wet is worse.

Yet wet AMD is also the form with an effective treatment. Anti-VEGF injections, discussed below, stop the leakage in most treated eyes, and some people regain vision they had lost. A person diagnosed with wet AMD early and treated consistently may keep reading vision for many years.

Dry AMD flips that picture. It is slower, kinder in its early stages, and the majority of people with it never lose the ability to read. But when it does reach geographic atrophy, the cells are gone, and no current treatment brings them back. The complement-inhibitor medicines now available for atrophy slow the growth of the patch on scans; in trials they did not restore vision. In that sense, late dry AMD is the harder problem, because the toolbox is smaller.

A more useful frame than worse is different kind of risk. Wet AMD is an emergency you can act on. Dry AMD is a marathon you manage. Both can end in legal blindness, defined by central vision too poor for driving or unaided reading, and both spare peripheral vision, so neither leads to total darkness.

The Mayo Clinic’s separate pages on the two forms make this point implicitly: the dry page is about slowing and supporting, the wet page is about intervening. Which is worse depends on which question you are really asking: about danger, or about hope.

Why treatment plans for dry vs wet macular degeneration differ so sharply

Treatments follow mechanisms. Wet AMD has a single, well-understood villain, the VEGF protein driving abnormal vessel growth, and medicine has a way to neutralize it. Block VEGF and the vessels stop leaking; keep blocking it and they stay quiet. The treatment is targeted because the target is clear.

Dry AMD has no such single villain. The disease reflects decades of cumulative stress on the RPE, involving oxidative damage, waste accumulation, chronic low-grade inflammation and the immune system’s complement cascade, a chain of proteins that normally helps clear debris but appears overactive in AMD. Genetics shape how vulnerable the RPE is; variants in complement genes are among the strongest known inherited risk factors. Smoking and diet layer on top. There is no leak to plug, only a slow decline to slow.

This is why the dry treatment plan looks like a portfolio rather than a prescription. The pieces include:

• Stopping smoking, which the NEI describes as roughly doubling AMD risk and remains the strongest modifiable factor.
• A diet rich in leafy greens, colorful vegetables and oily fish, associated in observational studies with lower risk.
• For intermediate disease, the antioxidant and zinc formula tested in AREDS and refined in AREDS2, taken under a clinician’s guidance.
• For geographic atrophy, complement-inhibitor injections in selected eyes.
• Low-vision rehabilitation and adaptive tools throughout.

Wet AMD treatment is more linear: confirm leakage on imaging, begin anti-VEGF, monitor, adjust intervals. Yet the two plans converge on one point. Every person with wet AMD also has the underlying dry disease process, so the lifestyle and monitoring pieces still apply. The plans differ because the emergencies differ, not because the eyes are fundamentally different.

Dry macular degeneration treatment: what is available and what the evidence shows

For most of the history of this disease, dry AMD treatment meant advice and a magnifier. That has shifted, but expectations need to stay grounded.

The best-evidenced intervention for intermediate dry AMD remains the AREDS formula. The original Age-Related Eye Disease Study, run by the NEI, found that a combination of specific antioxidant vitamins and zinc reduced the risk of progressing to advanced AMD by about 25 percent over five years in people with intermediate disease or advanced disease in one eye. AREDS2 later swapped one ingredient, beta-carotene, for the carotenoids lutein and zeaxanthin because beta-carotene raised lung cancer risk in smokers and the substitution performed at least as well. Two caveats matter. The formula did not help people with early AMD, and it is not a general eye vitamin; it was tested for one stage of one disease. Whether it suits you, and which formulation, is a conversation with your clinician, particularly if you smoke or take other supplements.

For geographic atrophy, complement-inhibitor medicines given by injection into the eye are now approved in some countries. Their trials showed that the atrophic patch grew more slowly in treated eyes than in untreated ones over one to two years. They did not show improvement in vision, and treated eyes had a higher rate of converting to wet AMD. Some guideline bodies have declined to recommend them on the balance of benefit and burden. This is an area where an honest specialist will say the evidence shows slowing on scans, not clearer sight.

Low-vision rehabilitation deserves more attention than it gets. Magnification, high-contrast lighting, text-to-speech tools and eccentric-viewing training, which teaches the eye to use a healthier patch of retina beside the damaged center, can restore independence even when they cannot restore cells.

Wet AMD treatment: how anti-VEGF eye injections work

The idea of an injection into the eye stops most people cold the first time they hear it. The procedure is quicker and far less dramatic than the phrase suggests, and understanding what it does makes it easier to accept.

Anti-VEGF medicines are proteins engineered to bind VEGF and prevent it from reaching the receptors on blood-vessel cells. Several exist, with generic names such as ranibizumab, aflibercept, bevacizumab and newer longer-acting molecules; which one is used is a decision for the treating team and often depends on local guidelines and the individual eye. With VEGF blocked, the abnormal vessels stop leaking and often shrink. Fluid under the retina is reabsorbed, the retinal layers settle back, and the distortion frequently eases. Because the medicine is gradually cleared from the eye, its effect wears off, and the vessels can reactivate. That is why treatment is repeated.

The injection itself takes seconds. The eye is numbed with drops or a small anesthetic injection, cleaned with antiseptic, and held open with a speculum. A very fine needle delivers the medicine through the white of the eye into the vitreous gel. Most people report pressure rather than pain, followed by a gritty sensation for a day and sometimes a small red patch on the white of the eye where a surface vessel was touched.

The NHS describes a typical pattern: injections monthly at first, then at intervals stretched or shortened according to what the OCT scan shows, an approach specialists call treat-and-extend. Some people settle at intervals of several months; others need frequent treatment for years.

Photodynamic therapy, in which a light-activated drug is infused and a cool laser directed at the leaking vessels, is an older approach now reserved for specific vessel patterns. Thermal laser has largely fallen out of use for AMD because it damages healthy retina too.

Who is usually offered injections, and who is asked to watch and wait

The decision to start anti-VEGF treatment is made on imaging, not on age or on how frightened the person is. The treating ophthalmologist is looking for active leakage: fluid within or beneath the retina on OCT, or a leaking vessel network on angiography, in an eye whose vision is still worth protecting. When those findings are present, guidelines from bodies such as the UK’s National Institute for Health and Care Excellence support prompt treatment, and prompt genuinely means within a short number of weeks, because visual recovery is better when fluid has not lingered.

People commonly offered injections include those with newly diagnosed wet AMD, those whose previously treated eye shows recurrent fluid, and those with wet AMD in the second eye after the first has been affected. Vision does not have to be poor to qualify; in fact, eyes treated while vision is still good tend to stay good.

Watch and wait applies to a different group. Early and intermediate dry AMD without leakage does not benefit from anti-VEGF, and injecting it would add risk for no gain. Geographic atrophy without wet features is monitored, with complement inhibitors discussed case by case. Some eyes with long-standing wet AMD that has already scarred are also observed rather than treated, because there is no active leak left to stop and the medicine cannot undo a scar.

Between those poles sits judgment. A tiny pocket of fluid in an eye that reads well may be watched at a shorter interval rather than injected. An eye with an active infection on the surface will have treatment deferred until it settles. People on blood thinners can usually still have injections, but the team will check. None of these are rules a patient can apply alone, which is precisely why the plan belongs to the treating team.

What the days and weeks after starting wet AMD treatment usually look like

The first evening after an injection is mostly about sensation. The eye feels scratchy, as though a lash is caught. Vision through it is blurred from the antiseptic and the numbing drops, and some people see a few floaters or a dark swirl for a day as the medicine disperses in the vitreous. A small bright-red patch on the white of the eye is common and harmless; it is a surface bleed, not bleeding inside the eye, and it fades over a week or two. The Mayo Clinic lists redness, discomfort, floaters and raised eye pressure among the typical short-lived effects.

Within the first two weeks, if the medicine is working, distortion often begins to settle. Straight lines straighten. The gray patch may lighten. Improvement is not guaranteed and is more likely when treatment started early; some eyes stabilize rather than improve, and stabilizing is itself the primary goal.

A month or so later comes the second injection and the first repeat OCT scan. The scan is the real report card. The clinician is looking for the dark fluid pockets to have shrunk or disappeared. After an initial series of monthly visits, the interval is typically stretched by a couple of weeks at a time if the retina stays dry, and pulled back if fluid reappears. Over the first year most people attend somewhere between six and a dozen appointments; the exact number depends on how the eye responds, which nobody can predict in advance.

Life largely carries on. Most people can read, cook and walk normally the next day, though driving on the day of the injection is unwise while vision is blurred. The routine becomes familiar quickly. What matters more than any single visit is not missing one, because gaps are when fluid returns.

Can dry macular degeneration be fixed?

If fixed means returning the macula to how it was at forty, no. Cells that have died in geographic atrophy do not regrow, and no approved treatment replaces them. Research into RPE cell transplants and gene therapies is active and genuinely promising, but it remains in trials, and an honest explainer has to say so plainly rather than hint at breakthroughs around the corner.

If fixed means slowed, protected and worked around, the answer is considerably more encouraging, and it is where most people’s real-world outcomes are decided.

Slowing is possible at the intermediate stage through the AREDS-type formula, with the evidence limits described earlier, and through stopping smoking, which matters even after diagnosis. Controlling blood pressure and cholesterol is reasonable on general health grounds and may help the choroid, though the AMD-specific evidence is weaker than for smoking.

Protecting means catching conversion to wet AMD early. Every person with dry AMD in one or both eyes should know what distortion looks like and know exactly whom to call if it appears. That single piece of preparation prevents more vision loss than any supplement.

Working around is the domain of low-vision rehabilitation, and it is chronically underused. Eccentric viewing trains the brain to read using a patch of retina just off-center that still works. Electronic magnifiers, high-contrast large-print, audiobooks, voice assistants and adjusted lighting turn a disabling blur into a manageable inconvenience for many people. Occupational therapists and low-vision optometrists specialize in this, and a referral is worth asking for at any stage.

So: dry AMD cannot be reversed with today’s medicine. It can be slowed, watched, and lived with well, which is a different thing from being fixed but a long way from being helpless.

What people often get wrong about macular degeneration

Nearly every clinic conversation about AMD involves gently correcting at least one of the following.

It will make me blind. AMD damages central vision. Peripheral vision, the wide field you use to walk around a room and notice movement, is preserved. People with even advanced AMD retain useful sight for mobility and daily tasks, and the NEI stresses this distinction.

Dry always turns into wet. It does not. The Cleveland Clinic figure of roughly 10 to 15 percent means the large majority of people with dry AMD never develop leakage. Vigilance is warranted; inevitability is not.

Wet is just late-stage dry. Wet AMD is a distinct process, new vessel growth, that can occur at the intermediate stage. An eye can develop wet AMD without ever reaching geographic atrophy, and an eye can reach geographic atrophy without ever becoming wet.

Eye vitamins prevent AMD. The AREDS formula reduced progression in people who already had intermediate disease. It did not prevent AMD in people without it, and a general multivitamin is not the same product. Supplements also interact with other medicines and conditions, which is why the decision belongs with a clinician.

Injections are a one-time fix. Anti-VEGF suppresses leakage while the medicine is present. Stopping early because vision improved is the commonest route to relapse. The NHS is explicit that treatment is ongoing.

Reading strains the eyes and speeds it up. There is no evidence that using your eyes wears them out. Reading, screens and fine work are safe. The one habit that clearly accelerates AMD is smoking.

It is caused by the sun. Ultraviolet exposure has been studied extensively and the link remains unproven. Sunglasses are sensible for comfort and for other eye conditions, but they are not an AMD treatment.

Questions to ask your care team about dry vs wet macular degeneration

A retina appointment moves fast, and the scan images on the screen can feel more like weather maps than medicine. Arriving with a short list of questions turns a passive experience into a shared plan. These are the ones that tend to unlock the most useful conversations.

• Which form do I have in each eye, and which stage? Dry and wet can differ between eyes, and the stage of the dry disease shapes everything else.
• What do you see on my OCT that worries you, and what looks stable? Asking to be shown the scan helps you recognize change later.
• Based on my drusen and pigment changes, what is my approximate risk of progression over the next few years? A specialist can tailor the AREDS-derived estimate to your eyes.
• Am I a candidate for the AREDS2-type formula, and does anything in my history, such as smoking, make one version preferable to another?
• If I have wet AMD: what is the plan for the interval between injections, and how will you decide when to extend or shorten it?
• What exactly should I watch for at home, and who do I call if I notice it, including out of hours?
• How often should my other eye be checked?
• Would a referral to low-vision rehabilitation help me now, rather than later?
• Are there clinical trials I might be eligible for, and what would participation involve?
• Is there anything about my driving, work or medications you need to know?

Write the answers down or ask permission to record them. Bringing a companion helps, because dilating drops leave your own vision blurry for hours afterward, and the details that matter, such as the exact interval to the next appointment, are easy to lose on the way home.

When to call your doctor

Macular degeneration is usually a slow condition, but two situations demand a same-day or next-day call to your eye care team, not a wait for the next routine appointment.

The first is any sudden change in central vision, particularly in an eye known to have dry AMD. New distortion, where straight edges such as door frames, tiles or lines of print bend or ripple; a new gray, dark or blank patch in the center of what you see; a rapid drop in the clarity of reading vision over days; or a change in how large or small things look compared with the other eye. These are the patterns the NHS and Mayo Clinic describe for conversion to wet AMD, and treatment is most effective when started promptly. If you check with an Amsler grid and a line that was straight last week is now wavy, treat that as a reason to call rather than something to re-check in a month.

The second applies after an eye injection. Contact the treating clinic urgently, at any hour, if in the days following treatment you develop increasing eye pain, worsening redness, a sudden shower of new floaters or flashes, a curtain or shadow spreading across your vision, or a marked drop in sight in the treated eye. Serious infection inside the eye is rare but is a genuine emergency, and retinal detachment, where the retina peels from its base, needs urgent assessment. Mild grittiness, a small red spot and a few floaters for a day are expected; escalating symptoms are not.

Any sudden loss of vision in either eye, with or without AMD, warrants emergency care, as it can signal a blocked retinal blood vessel or stroke. When in doubt, call. The treating team would far rather see an eye that turns out to be fine than miss one that is not.

Frequently asked questions

What is worse, dry or wet macular degeneration?

Wet macular degeneration is more dangerous in the short term because untreated leakage can destroy central vision within months, and it accounts for most severe AMD vision loss. Dry AMD progresses far more slowly, but its advanced stage, geographic atrophy, cannot be reversed and has fewer treatment options. Wet AMD is an emergency with an effective treatment; dry AMD is a long-term condition to slow and manage. Neither causes total blindness, since peripheral vision is spared.

Does dry macular degeneration turn into wet?

Sometimes, but not usually. The Cleveland Clinic estimates that roughly 10 to 15 percent of people with dry AMD develop the wet form, meaning most never do. Risk is higher with large drusen, pigment changes, or wet AMD already present in the other eye. Conversion is an event rather than a stage, so it can happen after years of stability, which is why regular scans and home monitoring for new distortion matter.

How long does it take for dry macular degeneration to turn to wet?

There is no set timeline. Some eyes convert within a year or two of the first drusen appearing, while many never convert at all. When it does happen, the change itself is fast, often over days to a few weeks. The AREDS simplified severity scale shows five-year risk of advanced AMD ranging from under one percent to around one in two depending on retinal findings, which is why an individual estimate from your specialist is more useful than an average.

What are the hallmark signs of dry macular degeneration?

Early dry AMD typically has no symptoms and is found on a dilated eye exam or OCT scan, where drusen and pigment changes are visible beneath the macula. When symptoms develop they are gradual: needing brighter light to read, mild central blur, slightly faded colors, and difficulty in dim settings. In advanced disease a fixed blank spot appears in central vision. These changes have many other causes, so an eye examination is needed to identify them.

What are the main wet macular degeneration symptoms?

The classic sign is distortion: straight lines such as door frames, tiles or lines of print appear bent or wavy. People may also notice a gray, dark or blank patch in the center of vision, a rapid drop in reading clarity, or objects looking a different size in one eye than the other. The NHS notes these changes can develop over a few weeks. Sudden onset of any of them is a reason to contact an eye clinic promptly.

Can dry macular degeneration be fixed?

Not in the sense of restoring lost cells; no approved treatment regrows the retina, and cell and gene therapies remain in trials. It can, however, be slowed and managed. Stopping smoking, an AREDS-type formula for intermediate disease under clinical guidance, and, in selected eyes with geographic atrophy, complement-inhibitor injections that slow atrophy growth on scans are the current options. Low-vision rehabilitation can substantially restore independence even when it cannot restore sight.

What are the macular degeneration progression stages?

Clinicians describe three stages based on retinal findings. Early AMD means medium drusen with normal vision. Intermediate AMD means large drusen or pigment changes, sometimes with mild blur; this is the stage where the AREDS formula showed benefit. Late AMD is either geographic atrophy, the advanced dry form with permanent central cell loss, or wet AMD with leaking vessels. An eye can move to wet AMD from the intermediate stage without passing through atrophy.

What is the best dry macular degeneration treatment available now?

The strongest evidence supports the AREDS2 antioxidant and mineral formula for intermediate dry AMD, which reduced progression to advanced disease by about 25 percent over five years in the NEI studies, alongside stopping smoking and a diet rich in leafy greens and fish. For geographic atrophy, complement-inhibitor injections slow lesion growth but have not improved vision. Whether any of these suits you depends on your stage and health, and is a decision for your eye specialist.

How do anti-VEGF injections for wet AMD actually work?

They contain proteins that bind vascular endothelial growth factor, the signal driving abnormal blood vessel growth under the macula. Blocking it makes the leaky vessels stop leaking and often shrink, allowing fluid to clear and the retina to settle. Because the medicine is gradually cleared from the eye, injections are repeated, typically monthly at first and then at intervals adjusted according to OCT scans. Vision often stabilizes and sometimes improves, especially when treatment starts early.

Can you have dry macular degeneration in one eye and wet in the other?

Yes, and it is common. The dry disease process underlies both forms, and each eye can be at a different stage, with one eye developing leaking vessels while the other remains dry. Having wet AMD in one eye raises the risk that the fellow eye will convert, so specialists monitor the dry eye more closely, often with scans at each visit for the treated eye and clear instructions on what to watch for at home.

References

• National Eye Institute (NIH): Age-Related Macular Degeneration
• MedlinePlus: Macular Degeneration
• NHS: Age-related macular degeneration (AMD)
• Cleveland Clinic: Macular Degeneration

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.